Clinical Trial

A Study of DA-302168S in Participants With Overweight/Obesity

Name: A Study of DA-302168S in Participants With Overweight/Obesity — clinical trial record (NCT07629544)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: PANDA-1

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study aimed at evaluating the efficacy, safety, and pharmacokinetic (PK) characteristics of DA-302168S tablets in overweight or obese participants in China.

Protocol Amendment History 1 change

critical Recruitment opened 2026-08-07

Trial Details

NCT Number	NCT07629544
Lead Sponsor	Chendu DIAO Pharmaceutical Group CO., LTD. Collaborators: Peking University People's Hospital
Conditions	Overweight and Obesity
Enrollment	840 participants
Start Date	2026-06-19
Primary Completion	2027-07-09 (estimated)
Study Completion	2027-10-19 (estimated)
Updated on ClinicalTrials.gov	2026-08-06